ERBB2 and breast carcinoma: In 2023, the ASCO/CAP published an update in their HER2 testing in breast cancer guidelines, recognizing the clinical relevancy of distinguishing IHC 0 from 1+ considering the new indication of T-DXd for HER2 IHC 1+ or IHC 2+/ISH-negative disease [31].